Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Prescription? No Problem: FDA Draft Rule Gives Green Light To OTC Hearing Aids

Executive Summary

The US FDA’s proposed reg, released on 19 October, aims to get more hearing aids into the ears of those who need them by allowing the devices to be purchased over the counter.

You may also be interested in...



A Year Of Extraordinary Health Challenges: CDRH Annual Report

In its 2021 annual report, the US FDA’s Center for Devices and Radiological Health outlines what it sees as list of accomplishments in a year director Jeff Shuren says was perhaps the busiest in the center’s history.

Senators, State AGs Differ On Whether Further Federal Regulation Needed For OTC Hearing Aids

Sens. Warren and Grassley say federal regulation is needed to ensure consumers in all states benefit from OTC hearing aids. State AGs, on the other hand, have asked the FDA to “define preemption terms in a way that recognizes the important role state and local entities play in protecting consumers.”

Comments On US FDA OTC Hearing Aid Proposed Rule Urge Clarification On Recommended Users

More than 1,000 comments were submitted by professional and civic organizations, trade groups and consumers FDA proposed rule on allowing OTC sales of hearing aids intended for consumers with mild to moderate hearing loss.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

MT144599

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel